New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials

NCT ID NCT06959641

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
XL092 (a tyrosine kinase inhibitor)
What this could lead to
If successful, this could provide a new first-line treatment option to control advanced thyroid cancer that no longer responds to radioiodine therapy.
What could go wrong
This is a small early-phase trial with only 33 participants, so results may not apply broadly. The drug may cause side effects or fail to slow cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED DIFFERENTIATED THYROID GLAND CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Harbor-UCLA Medical Center

    RECRUITING

    Torrance, California, 90502, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.